Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
EPI-001, ARv7, and TNBC Evidence
2026-10-14
A source-grounded overview of research linking androgen receptor variant 7 with outcomes in triple-negative breast cancer and evaluating EPI-001 as a pharmacologic research probe, with emphasis on study limitations and translational boundaries.
Exo1 and Tumor EV Research: Evidence Overview
2026-10-13
The cited Nature Cancer study presents a lipidated nanophotosensitizer designed to trace and disable tumor extracellular vesicles (TEVs) while treating primary tumors in mouse models. Its findings support a preclinical concept linking intracellular photodynamic therapy with disruption of TEV-mediated communication, but they do not establish clinical efficacy or show that Exo1 was used. Exo1, also known as methyl 2-(4-fluorobenzamido)benzoate, is relevant to exocytic pathway research as a distinct chemical tool for studying membrane traffic.
Hydroxychloroquine Sulfate: Identity and Scope
2026-10-13
A source-limited overview of the listed compound’s chemical identity, proposed research scope in autoimmune disease research, and the absence of matched primary evidence.
Protease Inhibition and the PSMD14–CARM1 Axis
2026-10-12
A 2025 study links PSMD14-mediated stabilization of CARM1 with FERMT1 transcription and hepatocellular carcinoma phenotypes. The findings provide a mechanistic cancer research model, but they do not establish that a broad protease inhibitor library, including the DiscoveryProbe™ Protease Inhibitor Library, was used in the study or would reproduce its effects.
How Impending Cell Death May Shape Metastasis
2026-10-12
A Cell Reports study proposed that tumor cells surviving impending death can acquire prometastatic states called PAMEs, recruit neighboring PIMs through cytokine signaling, and contribute to distant metastasis. The findings are mechanistically suggestive but remain bounded by model-system, pharmacological-specificity, and clinical-validation limits.
Proteinase K and Evidence Quality in Genome Editing
2026-10-11
Proteinase K is more than a broad-spectrum serine protease for DNA preparation: it can be understood as a preanalytical variable in genome-editing evidence. This article connects DNA integrity preservation during protein digestion with the interpretation limits of the ABE9-SpRY mouse-model study.
Neurospora crassa IPA Pathway and Auxin Biosynthesis
2026-10-10
Sardar and Kempken characterized an indole-3-pyruvic acid pathway for indole-3-acetic acid production in the non-pathogenic fungus Neurospora crassa. By combining computational gene identification, metabolite analysis, and targeted genetic perturbation, the study connected IPA metabolism with IAA production and conidiation while also defining important limits on cross-species interpretation.
UGDH Phosphorylation and Enzalutamide Resistance
2026-10-09
The reference study identifies UGDH serine 316 phosphorylation as a regulatory connection between kinase signaling, glycosaminoglycan production, tumor-cell behavior, and enzalutamide resistance. Its findings suggest that metabolic remodeling may influence treatment response in prostate cancer, while also defining important boundaries around model system, mutation-based inference, and clinical applicability.
Hematoxylin and Eosin Staining Kit K1142 Overview
2026-10-08
APExBIO’s Hematoxylin and Eosin Staining Kit (SKU K1142) is a research-use reagent set described for tissue morphology visualization and cytological preparations. No matched paper evidence was provided, so independent performance and reproducibility cannot be assessed.
Letrozole in Breast Cancer Research: Evidence and Limits
2026-10-08
This source-grounded overview examines Letrozole as a non-steroidal aromatase inhibitor in breast cancer research. It distinguishes supplier-reported pharmacology from peer-reviewed clinical evidence, outlines conceptual applications in estrogen-dependent models, and evaluates claims involving estrogen receptor alpha downregulation, FSH release modulation, and neural endpoints. The discussion emphasizes evidence strength, provenance, model dependence, and the limits of extrapolating product descriptions or toremifene studies to Letrozole.
METTL3–LEPR m6A Signaling in Fetal Growth Restriction
2026-10-07
Li and colleagues connect reduced METTL3 activity, N6-methyladenosine modification, and LEPR dysregulation with fetal growth restriction through complementary human, mouse, and trophoblast-cell evidence. The study identifies an m6A–LEPR axis that may influence trophoblast behavior, while its biomarker and therapeutic implications remain provisional because of model, specificity, and study-design limitations.
Masitinib (AB1010) Product Overview
2026-10-07
Masitinib (AB1010), SKU A2942, is described by APExBIO as a phenylaminothiazole-type tyrosine kinase inhibitor associated with KIT and PDGFR research. No matched paper evidence was supplied, so performance, mechanisms, and disease-related outcomes cannot be independently assessed here.
CH 223191: From AhR Blockade to Translation
2026-10-06
A translational perspective on CH 223191 as an aryl hydrocarbon receptor antagonist, using ovarian follicle evidence to distinguish AhR-dependent toxicity from correlation while defining the boundaries of pharmacological interpretation.
AMPK–p62 Feedback Under Metabolic Stress
2026-10-06
A 2024 Autophagy study identifies a double-positive feedback loop linking AMPK and SQSTM1/p62 during metabolic stress. The work connects lysosomal deacidification, TFEB/TFE3 regulation, TAK1 signaling, KEAP1 turnover, and NRF2 activation into a mechanistic model of coordinated antioxidant adaptation in cancer-related settings.
What Commercial Protease Libraries Reveal for SARS-CoV-2
2026-10-05
Kralj, Jukič, and Bren reviewed commercial molecular libraries designed for SARS-CoV-2 targets, protease inhibition, and protein–protein interaction disruption. Their central contribution is a critical assessment of library-design transparency: commercial collections often combine ligand- and structure-based filtering, yet provide limited information needed to judge chemical-space coverage, docking reliability, selectivity, or freedom from screening liabilities.